Patents Assigned to Genentech
  • Publication number: 20230313189
    Abstract: The present invention relates to complement component 4 (C4) inhibitors for use in treatment of a neurological disease. The invention in particular relates to the use of C4 inhibitors for down-regulation of C4 expression. The invention also relates to nucleic acid molecules, which are complementary to C4A and/or C4B and capable of reducing the level of an C4A and/or C4B mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment of a neurological disease.
    Type: Application
    Filed: November 9, 2022
    Publication date: October 5, 2023
    Applicant: Genentech, Inc.
    Inventors: Alexander MUNK, Helene M. GYLLING, Jesse Eric HANSON, Lukasz J. KIELPINSKI
  • Publication number: 20230314420
    Abstract: Assays to analyze quality and quantity attributes of fixed dose combinations are provided. In particular, assays for fixed dose combinations of two anti-HER2 antibodies, and for subcutaneous formulations comprising pertuzumab and trastuzumab are described herein.
    Type: Application
    Filed: January 11, 2023
    Publication date: October 5, 2023
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Cécile AVENAL, Nadine HOLZMANN, Michael NOAK, Tania RUCHTY, Gabriele Maria SCHAEFER, Franziska ZAEHRINGER
  • Publication number: 20230310455
    Abstract: Provided are combination therapies comprising inavolisib (a.k.a. GDC-0077) and other HER2-targeted therapies (e.g., pertuzumab and trastuzumab) for the treatment of HER2-positive cancers; and methods of treating HER2 positive (HER2+) cancers in a patient (preferably a patient with a PIK3CA mutant breast cancer) comprising administering a therapeutically effective amount of inavolisib and a HER2-targeted therapy (e.g., trastuzumab, pertuzumab, or a combination of trastuzumab and pertuzumab).
    Type: Application
    Filed: June 9, 2023
    Publication date: October 5, 2023
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Jennifer Lee Schutzman, Chunyan Song, Kyung Wha Song, Eirini Thanopoulou, Simon Peter Warburton, Anwesha Dey, Stephanie Royer Joo
  • Publication number: 20230312473
    Abstract: Processes for preparing biheteroaryl compounds are provided, including the biheteroaryl compound 3-(difluoromethoxy)-5-[2-(3,3-difluoropyrrolidin-1-yl)-6-[(1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl]pyrimidin-4-yl]pyridin-2-amine. Among other advantages, the processes provide for: the use of solvents that are relatively non-toxic and inexpensive; reduced usage of expensive precious metal catalysts; reaction temperature reduction in certain steps; the use of relatively non-toxic oxidation agents; the use of inexpensive transition metal catalysts; a reduction of molar ratios of certain reactants thereby improving process efficiency while reducing cost and waste; significantly higher reactant concentrations in certain steps; elimination of the need for multiple chromatographic purification steps; elimination of the need for certain extraction steps using organic solvent; and provide for higher yield and improved purity.
    Type: Application
    Filed: March 31, 2023
    Publication date: October 5, 2023
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Fabienne HOFFMANN-EMERY, Manuel KONRATH, Christian LAUTZ, Katrin Monika NIEDERMANN, Jonathan Ugo ORCEL, Diane Elizabeth CARRERA
  • Patent number: 11771843
    Abstract: A syringe (18) has a longitudinal body (28) with an interior (228) in which a pharmaceutical substance is arranged, a needle connected to one longitudinal end of the body (228) and a rigid needle shield (38) encasing the needle. The rigid needle shield (38) is essentially water vapour tight. The syringe (18) according to the invention allows for preventing needle clogging and, thus, proper provision of pharmaceuticals, particularly by subcutaneous, intramuscular or ocular injection.
    Type: Grant
    Filed: February 18, 2022
    Date of Patent: October 3, 2023
    Assignees: HOFFMANN-LA ROCHE INC., GENENTECH, INC.
    Inventors: Frank Bamberg, Heather L. Flores, Robert Müller, Elisabeth Schaible, Edward Schwarb, Lionel Vedrine, Kewei Yang, Mathieu Rigollet, Pierre Goldbach, Baboo Dushyantsingh Goordyal, Ivy Lin, Florian Wildenhahn
  • Publication number: 20230305813
    Abstract: The present disclosure relates to techniques for continuous integration and continuous deployment of source code on a digital health platform. Particularly, aspects are directed to receiving source code from a software development system (the source code being validated in accordance with a first QMS), generating a profile for the source code, classifying the source code into a class of code based on the profile, retrieving a second QMS associated with the class of code, validating the source code in accordance with the second QMS, upon validation of the source code, executing a build process to generate a executable program from the source code, encapsulating the executable program in a container, and deploying the container on one or more nodes of a software platform. The first QMS is adapted from the perspective of the software development system; whereas the second QMS is adapted from the perspective of the software platform.
    Type: Application
    Filed: April 24, 2023
    Publication date: September 28, 2023
    Applicant: GENENTECH, INC.
    Inventors: Niaz Ahsan Jalal, Abdesslem Dridi
  • Publication number: 20230303682
    Abstract: The invention provides anti-Notch2 antibodies and methods of using the same.
    Type: Application
    Filed: July 16, 2021
    Publication date: September 28, 2023
    Applicant: Genentech, Inc.
    Inventors: Cecilia Pui Chi Chiu, Yan Wu, Adel Mahmoud ElSohly, Daniel George Lafkas, Jian Mehr-Dean Payandeh, Hoangdung Dang Ho, Siao-Ping Tsai
  • Patent number: 11767362
    Abstract: The invention provides compositions and methods for treating cancers. The methods comprising administering a PD-1 axis binding antagonist and an anti-GPC3 antibody. The compositions comprising a pharmaceutical composition for treating cancer which comprises a PD-1 axis binding antagonist and an anti-GPC3 antibody. Also disclosed are a pharmaceutical composition to be used in combination with a PD-1 axis binding antagonist for treating cancer which comprises an anti-GPC3 antibody as the active ingredient; and a pharmaceutical composition to be used in combination with an anti-GPC3 antibody for treating cancer which comprises as the active ingredient a PD-1 axis binding antagonist.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: September 26, 2023
    Assignees: Chugai Seiyaku Kabushiki Kaisha, Genentech, Inc.
    Inventors: Mika Endo, Atsuhiko Kato, Toshihiko Ohtomo, Kenji Adachi, Yasuko Kinoshita, Yoshinori Narita
  • Patent number: 11767312
    Abstract: Disclosed are a phthalazinone compound, and a preparation method therefor and the medical use thereof. In particular, disclosed are a compound as represented by formula (I), and a pharmacodynamically acceptable salt, and the use of the compound as an androgen receptor (AR) for degradation.
    Type: Grant
    Filed: April 5, 2023
    Date of Patent: September 26, 2023
    Assignee: GENENTECH, INC.
    Inventors: Hongfu Lu, Weiqiang Xing, Yongcong Lv, Baojian Qi, Jianbiao Peng, Haibing Guo
  • Patent number: 11767370
    Abstract: This present disclosure provides a process for concentrating proteins including an ultrafiltering, a diafiltering, and a second ultrafiltering sequence, at elevated temperatures, such as above about 30° C. The disclosure also includes a process of preparing highly concentrated antibody compositions. and highly concentrated antibody products.
    Type: Grant
    Filed: November 1, 2022
    Date of Patent: September 26, 2023
    Assignees: Genentech, Inc., Novartis AG
    Inventor: Charles M. Winter
  • Publication number: 20230296620
    Abstract: The present application relates to systems and methods for assaying presence of large molecule analytes, such as proteins, e.g., antibodies, antigens, receptors, and the like, using a targeted two-dimensional liquid chromatography, tandem mass spectrometry (2D-LC-MS/MS) system, optionally combined with affinity capture. In some aspects, the system is partially or fully automated. In some aspects, the system may allow detection of protein biomarkers (e.g., antibodies or antigens) from clinical or nonclinical biological tissue or fluid samples in the pg/mL to ng/mL range.
    Type: Application
    Filed: October 13, 2022
    Publication date: September 21, 2023
    Applicant: Genentech Inc.
    Inventors: Keyang Xu, Jintang He, Surinder Kaur
  • Patent number: 11760753
    Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: September 19, 2023
    Assignee: Genentech, Inc.
    Inventors: Marie-Gabrielle Braun, Emily Hanan, Steven T. Staben, Robert Andrew Heald, Calum MacLeod, Richard Elliott
  • Patent number: 11760797
    Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of making and using the same, e.g., for treatment of IL-33 mediated disorders (e.g., ocular disorders such as AMD (e.g., geographic atrophy (GA)).
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: September 19, 2023
    Assignee: Genentech, Inc.
    Inventors: Gerald R. Nakamura, Dhaya Seshasayee, Menno Van Lookeren Campagne, Tiffany Wong, Jia Wu, Hongkang Xi, Jack Bevers, III, Hiu Nam Chan, Laetitia Comps-Agrar, Racquel Corpuz
  • Patent number: 11760744
    Abstract: Provided are fused ring compounds of Formula (I), Formula (II), or Formula (III), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods treatment by their administration.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: September 19, 2023
    Assignee: Genentech, Inc.
    Inventors: Aijun Lu, Sushant Malhotra, Alan G. Olivero, Cheng Shao, Yamin Zhang, Steven Do
  • Publication number: 20230287127
    Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Application
    Filed: January 26, 2023
    Publication date: September 14, 2023
    Applicant: Genentech, Inc.
    Inventors: Bryan IRVING, Henry CHIU, Heather MAECKER, Sanjeev MARIATHASAN, Sophie M. LEHAR, Yan WU, Jeanne CHEUNG
  • Publication number: 20230288409
    Abstract: This disclosure relates to methods of preparing re-usable and dry-able cartridges comprising matrices comprising a detection molecule such as an antibody, for detection or enrichment of an analyte in a sample, such as an antigen recognized by an antibody. In some embodiments, the cartridge comprises a tube or well that holds the matrix. In some embodiments, the matrix or associated cartridges may be stored wet or dry. The disclosure also relates to the cartridges and methods of their use.
    Type: Application
    Filed: May 18, 2023
    Publication date: September 14, 2023
    Applicant: Genentech Inc.
    Inventor: Samuel Benjamin Pollock
  • Publication number: 20230287133
    Abstract: Disclosed herein are compositions and methods for the treatment of systemic lupus erythematosus using anti-CD20/anti-CD3 bispecific antibodies, such as mosunetuzumab.
    Type: Application
    Filed: November 15, 2022
    Publication date: September 14, 2023
    Applicant: Genentech, Inc.
    Inventors: Susan Lee LIMB, Matthew Dominic CASCINO, Monique NICOLL, Jay Prakash GARG, Michael Zecong LIAO
  • Patent number: 11753464
    Abstract: Anti-K63-linked polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: September 12, 2023
    Assignee: Genentech, Inc.
    Inventors: Robert F. Kelley, Marissa L. Matsumoto
  • Publication number: 20230279067
    Abstract: The invention provides an effectorless immunoglobulin Fc protein, fusions of the effectorless Fc protein to a Flt3 ligand, and methods of using the same.
    Type: Application
    Filed: November 21, 2022
    Publication date: September 7, 2023
    Applicant: Genentech, Inc.
    Inventors: Yichin LIU, Christine Carine MOUSSION, Travis William BAINBRIDGE, lraj HOSSEINI, Gregory Alan LAZAR, Sivan COHEN, Christopher Charles KEMBALL, Jill M. SCHARTNER
  • Publication number: 20230279012
    Abstract: Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: December 20, 2022
    Publication date: September 7, 2023
    Applicant: Genentech, Inc.
    Inventors: James John CRAWFORD, Daniel Fred ORTWINE, BinQing WEI, Wendy B. YOUNG